American Century Companies’s Ventyx Biosciences VTYX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-99,499
| Closed | -$898K | – | 2933 |
|
|
2025
Q4 | $898K | Buy |
99,499
+30,086
| +43% | +$225K | ﹤0.01% | 2351 |
|
|
2025
Q3 | $216K | Buy |
+69,413
| New | +$184K | ﹤0.01% | 2686 |
|
|
2025
Q1 | – | Sell |
-67,329
| Closed | -$147K | – | 2961 |
|
|
2024
Q4 | $147K | Buy |
67,329
+7,414
| +12% | +$16.8K | ﹤0.01% | 2814 |
|
|
2024
Q3 | $131K | Buy |
59,915
+34,032
| +131% | +$78.3K | ﹤0.01% | 2815 |
|
|
2024
Q2 | $59.8K | Buy |
+25,883
| New | +$108K | ﹤0.01% | 2851 |
|
|
2024
Q1 | – | Sell |
-476,542
| Closed | -$1.18M | – | 2966 |
|
|
2023
Q4 | $1.18M | Buy |
476,542
+228,640
| +92% | +$2.17M | ﹤0.01% | 1993 |
|
|
2023
Q3 | $8.61M | Sell |
247,902
-2,323
| -0.9% | -$80.3K | 0.01% | 1118 |
|
|
2023
Q2 | $8.21M | Buy |
250,225
+1,037
| +0.4% | +$35.7K | 0.01% | 1137 |
|
|
2023
Q1 | $8.33M | Sell |
249,188
-46,900
| -16% | -$1.82M | 0.01% | 1082 |
|
|
2022
Q4 | $9.71M | Sell |
296,088
-2,090
| -0.7% | -$61.9K | 0.01% | 982 |
|
|
2022
Q3 | $10.4M | Sell |
298,178
-124,607
| -29% | -$2.76M | 0.01% | 883 |
|
|
2022
Q2 | $5.17M | Buy |
422,785
+29,916
| +8% | +$447K | ﹤0.01% | 1108 |
|
|
2022
Q1 | $5.33M | Buy |
392,869
+119
| +0% | +$1.59K | ﹤0.01% | 1095 |
|
|
2021
Q4 | $7.8M | Buy |
+392,750
| New | +$7.44M | ﹤0.01% | 947 |
|
Other funds holding VTYX
American Century Companies's VTYX Position: Q1 2026 in Review
American Century Companies sold out of Ventyx Biosciences (VTYX) in Q1 2026, closing a stake of 99,499 shares — an estimated $898K sold.
American Century Companies first reported a position in VTYX in Q4 2021 and held it in 14 quarters. The position peaked at $10.4M in Q3 2022. 1 fund tracked by Wall St. Rank holds VTYX as of Q1 2026.
- American Century Companies reported no remaining Ventyx Biosciences position as of Q1 2026 after selling out during the quarter.
- American Century Companies sold 99,499 Ventyx Biosciences shares in Q1 2026, an estimated $898K.
- American Century Companies first reported a position in Ventyx Biosciences in Q4 2021 and held it in 14 quarters.
- American Century Companies's Ventyx Biosciences position peaked at $10.4M in Q3 2022.
- 1 fund tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2026.
Based on American Century Companies's 13F filing for Q1 2026, filed 15 May 2026.